Currently Available Urine-Based Tumour Markers in the Detection of New and Recurrent Urothelial Bladder Cancer

Abstract

Context: The current study aimed at providing an evidence -based and up-to-date review of the literature regarding the assessment and outcomes of pregnancy in patients with renal transplant. Design: It was a review of the current literature. Conclusions: According to the current study findings, the function or survival of renal allograft was not adversely affected by getting pregnant. Therefore, ideal care for these patients needs a multidisciplinary approach including maternal-fetal medicine, nephrology, and neonatology specialists.

A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection

“…Despite the large and growing list of candidate protein markers for UCB (5)(6)(7)(8)(9)(10)(11), as yet none have entered routine clinical use. There is no doubt that clinicians need better methods for individual patients' treatments and follow-up regimens selection.…”

“…Generally, after haematuria, most patients experience a similar clinical process (5,6). There were also several biomarkers used for diagnostic and monitoring purposes, but no marker has yet been shown to reduce the need for cystoscopy (6)(7)(8)(9)(10)(11). This is especially problematic given the high recurrence rate, because of which lifelong surveillance is needed to detect any recurrence as early as possible (10).…”

“…There were also several biomarkers used for diagnostic and monitoring purposes, but no marker has yet been shown to reduce the need for cystoscopy (6)(7)(8)(9)(10)(11). This is especially problematic given the high recurrence rate, because of which lifelong surveillance is needed to detect any recurrence as early as possible (10). The development of reliable, non-invasive tests could therefore improve not only the UCB diagnosis itself but also the quality of life for patients with a disease history, and in this regard the detection of biomarkers in bodily fluids has shown a high potential (4)(5)(6)(7)(8)10).…”

“…This is especially problematic given the high recurrence rate, because of which lifelong surveillance is needed to detect any recurrence as early as possible (10). The development of reliable, non-invasive tests could therefore improve not only the UCB diagnosis itself but also the quality of life for patients with a disease history, and in this regard the detection of biomarkers in bodily fluids has shown a high potential (4)(5)(6)(7)(8)10). The US Food and Drug Administration (FDA) has approved only a few urine-based tests, and there are currently no blood based tests (6,10).…”

“…The development of reliable, non-invasive tests could therefore improve not only the UCB diagnosis itself but also the quality of life for patients with a disease history, and in this regard the detection of biomarkers in bodily fluids has shown a high potential (4)(5)(6)(7)(8)10). The US Food and Drug Administration (FDA) has approved only a few urine-based tests, and there are currently no blood based tests (6,10). Therefore, more novel biomarkers are urgently needed to detect UCB in general and especially in high-risk populations where the disease prevalence appears to be high (12,13).…”